IMPORTANT COVID-19 UPDATES

9780521115612

Progress in Neurotherapeutics and Neuropsychopharmacology

by
  • ISBN13:

    9780521115612

  • ISBN10:

    0521115612

  • Edition: 1st
  • Format: Paperback
  • Copyright: 2009-08-27
  • Publisher: Cambridge University Press
  • Purchase Benefits
  • Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • Get Rewarded for Ordering Your Textbooks! Enroll Now
List Price: $43.99 Save up to $2.20
  • Buy New
    $41.79
    Add to Cart Free Shipping

    USUALLY SHIPS IN 24-48 HOURS

Supplemental Materials

What is included with this book?

Summary

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Table of Contents

Contributors
Progress in neurotherapeutics and neuropsychopharmacology
Trifusal versus aspirin for the prevention of stroke Antonio Culebras
The Argatroban and tPA stroke study
Use of Selegiline as monotherapy and in combination with Levodopa in the management of Parkinson's disease: perspectives from the MONOCOMB study
Ropinirole 24-h prolonged release in advanced Parkinson's disease: review of a randomised, double-blind, placebo-controlled study (EASE PD - adjunct study)
Insulin resistance and Alzheimer's disease: pathophysiology and treatment
Targeting Amyloid with Tramiprosate in patients with mild-to-moderate Alzheimer's disease
Intranasal Zolmitriptan is effective and well-tolerated in acute cluster headache: a randomized placebo-controlled double-blind crossover
Optimal dosing of immunomodulating drugs: a dose-comparison study of GA in RRMS
Tetrathiomolybdate versus Trientine in the initial treatment of neurologic Wilson's disease
Randomized clinical trials of Pregabalin for neuropathic pain: methods, results, and implications
Effect of Methylphenidate in patients with acute traumatic brain injury: a randomized clinical trial
Improvement in speeded cognitive processing after anti-epileptic drug withdrawal - a controlled study in mono-therapy patients
A randomized-controlled trial of bilateral rTMS for treatment-resistant depression
Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder
Night eating syndrome and results from the first placebo-controlled trial of treatment, with the SSRI medication, Sertraline: implications for clinical practice
Modafinil: a candidate for pharmacotherapy of negative symptoms in schizophrenia
New approaches to treatment of schizophrenia by enhancing N-methyl-D-aspartate neurotransmission
Subject index
Author index
Table of Contents provided by Publisher. All Rights Reserved.

Rewards Program

Write a Review